Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation

R. Mark Ghobrial, MD

Status: Completed

Conditions: End Stage Liver Disease

Treatments: Drug: Enteric-coated Mycophenolate Sodium

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01467011

Pro00004722

Details and patient eligibility

About

The purpose of this study is to gather information regarding the use of Myfortic, Prograf, and corticosteroids in new liver transplant recipients. These three medicines help to prevent the body from rejecting the transplanted liver. The information the investigators are obtaining is data relating to the process of Myfortic absorption by the body, its distribution in the body, the breakdown of Myfortic in the body, and its elimination from the body. This absorption, distribution, breakdown, and elimination is called pharmacokinetics.

Full description

Myfortic is approved for use in kidney transplant recipients, and has been prescribed by doctors for liver transplant recipients. No study has been reported to date evaluating the pharmacokinetics of Myfortic in new liver transplant recipients who also take Prograf and corticosteroids. During this six month study, a series of blood samples will be obtained after subjects take Myfortic, Prograf, and corticosteroids.

Enrollment: 25 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults > or equal to age 18 years
• Planned to receive tacrolimus and corticosteroid therapy posttransplant
• Serum creatinine at transplant < or equal to 2.5mg/dL
• UCSF tumor staging < 8cm total
• Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to the baseline visit and are required to practice a reliable method of contraception for the duration of the study and for no fewer than 6 weeks after completing the study.
• Signed informed consent form prior to any research assessment

Exclusion criteria

• Induction therapy
• Requiring dialysis at the time of transplant
• Organ transplant other than liver
• Pregnant or nursing females
• Women of childbearing potential not practicing reliable methods of contraception. Reliable methods for contraception include surgical sterilization (hysterectomy, bilateral tubal ligation), double-barrier method (such as condom and diaphragm). To be considered as post-menopausal and not of childbearing potential, female subjects must have experienced 12 consecutive months of amenorrhea.
• Require any medications that interfere with metabolism of Myfortic (other than corticosteroids)
• Have a known hypersensitivity to mycophenolate sodium, mycophenolic acid, mycophenolate mofetil, or any of its excipients
• Participation in a study of investigational drug in the previous 30 days or 5 half-lives of the investigational drug

Trial design

25 participants in 1 patient group

Cases

Description:

de novo liver transplant recipients receiving Enteric-coated Mycophenolate Sodium

Treatment:

Drug: Enteric-coated Mycophenolate Sodium